Omnicell, Inc.
General ticker "OMCL" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $1.6B (TTM average)
Omnicell, Inc. follows the US Stock Market performance with the rate: 15.7%.
Estimated limits based on current volatility of 2.7%: low 38.22$, high 40.10$
Factors to consider:
- Total employees count: 3670 (+0.5%) as of 2024
- US accounted for 91.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Strategic risks and growth management, Liquidity and credit risks, Regulatory and compliance, Cybersecurity threats
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [32.08$, 57.64$]
- 2025-12-31 to 2026-12-31 estimated range: [31.21$, 56.71$]
Financial Metrics affecting the OMCL estimates:
- Negative: with PPE of 26.0 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 0.03
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 9.23
- Positive: 41.86 < Shareholder equity ratio, % of 58.62 <= 63.39
- Positive: Inventory ratio change, % of -7.35 <= -0.75
- Positive: -4.48 < Investing cash flow per share per price, % of -2.59
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of 0.59
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term OMCL quotes
Long-term OMCL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,295.95MM | $1,147.11MM | $1,112.24MM |
| Operating Expenses | $1,298.27MM | $1,181.98MM | $1,111.90MM |
| Operating Income | $-2.32MM | $-34.87MM | $0.34MM |
| Non-Operating Income | $-0.13MM | $14.76MM | $25.26MM |
| R&D Expense | $104.97MM | $97.11MM | $90.41MM |
| Income(Loss) | $-2.45MM | $-20.11MM | $25.59MM |
| Taxes | $-8.10MM | $0.26MM | $13.06MM |
| Profit(Loss)* | $5.65MM | $-20.37MM | $12.53MM |
| Stockholders Equity | $1,130.14MM | $1,188.95MM | $1,243.31MM |
| Inventory | $147.55MM | $110.10MM | $88.66MM |
| Assets | $2,210.76MM | $2,226.88MM | $2,120.96MM |
| Operating Cash Flow | $77.78MM | $181.09MM | $187.72MM |
| Capital expenditure | $60.74MM | $41.47MM | $36.46MM |
| Investing Cash Flow | $-58.67MM | $-55.02MM | $-52.79MM |
| Financing Cash Flow | $-20.95MM | $23.42MM | $-235.58MM |
| Earnings Per Share** | $0.13 | $-0.45 | $0.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.